Pentylenetetrazol

Pentylenetetrazol

Systematic (IUPAC) name
6,7,8,9-Tetrahydro-5H-tetrazolo(1,5-a)azepine
Identifiers
CAS Number	54-95-5 Y
ATC code	R07AB03 (WHO)
PubChem	CID: 5917
ChemSpider	5704 N
UNII	WM5Z385K7T N
KEGG	D07409 N
ChEBI	CHEBI:34910 N
ChEMBL	CHEMBL116943 N
Chemical data
Formula	C6H10N4
Molecular mass	138.171 g/mol
SMILES C12=NN=N[N]1CCCCC2
InChI InChI=1S/C6H10N4/c1-2-4-6-7-8-9-10(6)5-3-1/h1-5H2 N Key:CWRVKFFCRWGWCS-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Pentylenetetrazol, also known as pentylenetetrazole, metrazol, pentetrazol (INN), pentamethylenetetrazol, Corazol, Cardiazol or PTZ, is a drug formerly used as a circulatory and respiratory stimulant. High doses cause convulsions, as discovered by the Hungarian-American neurologist and psychiatrist Ladislas J. Meduna in 1934. It has been used in convulsive therapy, and was found to be effective—primarily for depression—but side-effects such as uncontrolled seizures were difficult to avoid. In 1939 pentylenetetrazol was replaced by electroconvulsive therapy, easier to administer, as the preferred method for inducing seizures in England's mental hospitals. In the US its approval by the FDA was revoked in 1982. It is used in Italy as a cough suppressant.

Mechanism

The mechanism of pentylenetetrazol is not well understood, and it may have multiple mechanisms of action. In 1984, Squires et al. published a report analyzing pentylenetetrazol and several structurally related convulsant drugs. They found that in vivo convulsant potency was strongly correlated to in vitro affinity to the picrotoxin binding site on the GABA-A receptor complex. Many GABA-A ligands are effective anticonvulsants, such as the sedatives diazepam and phenobarbital, but presumably pentylenetetrazol has the opposite effect when it binds to the GABA-A receptor.

Several studies have focused on the way pentylenetetrazol influences neuronal ion channels. A 1987 study found that pentylenetetrazol increases calcium influx and sodium influx, both of which depolarize the neuron. Because these effects were antagonized by calcium channel blockers, it was concluded that pentylenetetrazol acts at calcium channels, and it causes calcium channels to lose selectivity and conduct sodium ions as well.

cAMP dependent mechanism

One study assessed the effect of cAMP, its analogs and dependent protein kinase on pentylenetetrazole-induced seizure in vivo. The finding show that cAMP analog, as well as phosphodiesterase and protein kinase inhibitors affected the epileptogenic activity of pentylenetetrazole. This finding shows the involvement of cAMP, its downstream and upstream on pentylenetetrazole activity.

Uses

Pentylenetetrazol has been used experimentally to study seizure phenomena and to identify pharmaceuticals that may control seizure susceptibility. Pentylenetetrazol is also a prototypical anxiogenic drug and, has been extensively utilized in animal models of anxiety. Pentylenetetrazol produces a reliable discriminative stimulus which is largely mediated by the GABA_A receptor. Several classes of compounds can modulate the pentylenetetrazol discriminative stimulus including 5-HT_1A, 5-HT₃, NMDA, glycine, and L-type calcium channel ligands.

Stanford University researchers proposed PTZ as a candidate for pharmacological treatment of Down syndrome. A brief communication in the April 2007 issue of Nature Neuroscience outlined an experiment designed to test the underlying theory proposed to explain the purported efficacy of GABA_A antagonists in restoring the declarative memory deficits associated with the mouse model of human Down Syndrome. Ts65Dn mice injected with a 2-week regimen of either of two compounds picrotoxin or bilobalide (both GABA antagonists) showed marked improvements in both exploration and recognition of novel objects over controls injected with only saline. These results were duplicated in a second experiment with mice fed either plain milk or a combination of milk and a non-epileptogenic dose of PTZ daily for 17 days. PTZ-fed mice achieved novel object task scores comparable to wild-type (normal) mice. These improvements persisted at least 1 to 2 months after the treatment regimen. Not surprisingly these compounds' efficacies were accompanied by the normalization of Long-term potentiation in the dentate gyrus one month after the end of treatment, further suggesting persistent drug-mediated improvements in learning and memory.

The finding of pentylenetetrazol's effectiveness in treating a mouse model of Down syndrome has led to it being explored as a means of correcting other learning deficiencies. Specifically, hamsters denied their natural circadian rhythm (though not denied sleep) had their memory restored to near-normal levels when treated with pentylenetetrazol.

Analogs

Related molecule compound undecamethylenetetrazole, potential inverse GABAergic.